查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1372801

寡核苷酸合成市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按产品类型、按应用、最终用户、地区和竞争细分

Oligonucleotide Synthesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product Type, By Application, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

寡核苷酸合成市场到 2022 年价值 40.3 亿美元，预计在预测期内将呈现强劲成长，预计到 2028 年复合年增长率 (CAGR) 为 13.30%。

该市场在生物技术和製药行业中占据着重要地位，代表着尖端研究和治疗开发的交叉点。近年来，由于对应用于基因编辑、分子诊断和药物发现等各个领域的客製化寡核苷酸的需求不断增长，该行业经历了显着的扩张。这种激增可归因于基因组学、个人化医疗和基于 RNA 的疗法的快速发展，所有这些都严重依赖寡核苷酸的精确合成。随着世界各地的组织在基因组学研究和分子诊断方面进行大量投资，寡核苷酸合成市场已成为关键的推动因素，使科学家能够以无与伦比的精度获得高品质、客製化的遗传材料。

该市场的竞争格局由成熟的行业领导者和创新新创公司组成，形成了一个充满活力的生态系统。自动化合成平台和新型化学修饰等技术进步正在提高寡核苷酸生产的效率和适应性，推动进一步扩张。此外，监管部门的批准和行业标准在确保合成寡核苷酸的品质和安全性、增强企业和研究人员的信心方面发挥关键作用。

市场概况
预测期 2024-2028
2022 年市场规模 40.3亿美元
2028 年市场规模 85.2亿美元
2023-2028 年复合年增长率 13.30%
成长最快的细分市场 疗法
最大的市场 北美洲

随着生物技术和製药行业的不断发展和多元化，寡核苷酸合成市场有望持续扩张。能够提供具有成本效益的高品质寡核苷酸解决方案，同时保持在不断发展的技术和监管要求的最前沿的公司无疑将在这个充满活力的商业环境中蓬勃发展。该领域的战略伙伴关係、研究合作和投资不仅正在重塑生命科学的格局，而且有望在医疗保健和生物技术领域取得突破性进展。因此，寡核苷酸合成市场是商业世界创新与进步的基石。

主要市场驱动因素

基于RNA的治疗

基于 RNA 的治疗代表了製药业的变革前沿，它们对寡核苷酸合成市场产生了重大影响。这些疗法利用核糖核酸 (RNA) 分子（包括信使 RNA (mRNA)、小干扰 RNA (siRNA) 和反义寡核苷酸 (ASO)）的潜力来调节基因表现并治疗多种疾病。寡核苷酸合成是基于 RNA 的疗法的核心，因为它涉及针对疾病所涉及的特定基因序列或途径定制的合成 RNA 分子的精确设计和生产。

基因组研究的进展

基因组研究的进步促进了寡核苷酸合成市场的显着成长。基因组研究的重点是解码生物体的全部遗传物质，在次世代定序 (NGS) 和 CRISPR-Cas9 基因编辑等技术的推动下，基因组研究发展迅速。这些创新导致对客製化寡核苷酸（短 DNA 或 RNA 序列）的需求大幅增加，这些寡核苷酸是遗传分析、操作和定序的基本建构模组。

寡核苷酸合成市场为研究人员提供量身定制的遗传材料，在这场基因组学革命中发挥关键作用。科学家需要这些寡核苷酸进行多种应用，包括全基因组定序、基因表现谱、表观遗传学研究和功能基因体学。随着研究人员致力于破解疾病的遗传基础、识别生物标记并开发标靶疗法，对高品质、精确寡核苷酸的需求不断升级。

此外，单细胞基因组学的出现允许对异质组织内的单一细胞进行分析，这带来了额外的复杂性和对专门寡核苷酸的需求。该领域的研究人员严重依赖独特的寡核苷酸探针和引子来探索单细胞层面上基因表现和细胞多样性的复杂性。

主要市场挑战

效率和可扩展性

由于各种应用中对客製化寡核苷酸的需求不断增长，效率和可扩展性是寡核苷酸合成市场的关键挑战。效率对于确保合成过程不仅快速且精确且无错误至关重要。研究人员和製造商都需要可靠且一致的结果，任何低效率都可能导致延误、成本增加和研究结果受损。另一方面，可扩展性围绕着产业满足寡核苷酸不断增长的需求的能力，特别是随着基因组学、基因疗法和分子诊断的应用而不断扩大。在维持品质标准的同时扩大生产是一项复杂的工作，通常需要在基础设施、自动化和流程优化方面进行大量投资。

挑战在于在效率和可扩展性之间取得平衡。虽然自动化和高通量技术提高了效率，但确保它们可扩展以满足需求激增是一项持续的斗争。此外，长或高度修饰的寡核苷酸的合成可能特别具有挑战性，因为它可能需要专门的设备和製程。此外，某些地区的监管限制需要严格的品质控制和文件记录，这可能会影响效率和可扩展性工作。

成本限制

寡核苷酸合成市场的成本限制代表了影响研究和商业应用的多方面挑战。寡核苷酸是广泛的基因研究、诊断和治疗开发工作的重要组成部分。然而，它们的合成，尤其是在处理长序列或化学修饰序列时，可能成本高昂。预算有限的研究人员经常面临与采购客製化寡核苷酸相关的高额费用，这可能会限制他们的实验范围。此外，在基于 RNA 的疗法中，生产大量高品质的合成 RNA 分子（例如用于疫苗或基因疗法的 mRNA）可能涉及高昂的成本。平衡对具有成本效益的寡核苷酸的需求与精度和纯度的要求是该行业面临的持续挑战。

寡核苷酸合成市场的公司也面临成本相关的压力。虽然自动化和合成技术的进步在一定程度上提高了效率并降低了成本，但市场内的竞争需要有竞争力的价格。对于那些希望在投资研发以保持该领域领先地位的同时保持利润率的公司来说，这可能是一项挑战。此外，化学修饰或特殊序列的结合会显着增加生产成本，使成本效益方程式更加复杂。

主要市场趋势

治疗进展

治疗进步代表了寡核苷酸合成市场的关键趋势，开创了精准医学和标靶治疗的新时代。这一趋势的特点是基于 RNA 的疗法的开发和商业化，包括信使 RNA (mRNA) 疫苗和基因疗法，它们严重依赖客製化寡核苷酸合成。 mRNA 疫苗，以 Pfizer-BioNTech 和 Moderna 的 COVID-19 疫苗为例，已经证明了合成 RNA 分子在不使用弱化或灭活病毒的情况下引发免疫反应的变革潜力。寡核苷酸合成是这些疫苗的核心，产生精确设计的编码病毒抗原的 mRNA 序列。除了疫苗之外，寡核苷酸在基因治疗中也发挥着至关重要的作用，它们被用来修饰、修復或取代导致遗传性疾病的缺陷基因。

寡核苷酸合成市场是治疗进步不可或缺的一部分，因为它提供了高精度和纯度的必要原料—客製化设计的寡核苷酸。这使得研究人员和製药公司能够以前所未有的准确性和有效性开发基于 RNA 的疗法。随着基于 RNA 的治疗研究扩展到解决各种疾病，包括癌症、罕见遗传性疾病和自体免疫疾病，寡核苷酸合成市场有望呈指数级增长。它将继续作为医疗保健领域创新和进步的基石，提供满足全球医疗保健需求所需规模生产这些变革性疗法的手段。因此，对于那些致力于为这个充满活力且快速发展的领域做出贡献的公司来说，保持寡核苷酸合成技术的前沿至关重要。

基因编辑和 CRISPR-Cas9

基因编辑，特别是透过革命性的 CRISPR-Cas9 技术，已成为寡核苷酸合成市场的主要驱动力。 CRISPR-Cas9 是一种多功能基因组编辑工具，依赖寡核苷酸的精确设计和合成来靶向和修改生物体基因组内的特定 DNA 序列。寡核苷酸称为引导 RNA (gRNA)，经过合成工程改造以补充标靶 DNA，引导 Cas9 酶到达所需的基因组位置进行编辑。这项技术开启了基因研究的新可能性，使研究人员能够以前所未有的精度操纵基因，应用于从基础研究到治疗介入的各种应用。

寡核苷酸合成市场透过提供客製化设计的 gRNA 和用于基因编辑的供体 DNA 模板，在支援 CRISPR-Cas9 应用方面发挥关键作用。研究人员和生物技术公司需要这些寡核苷酸来促进精确修饰，例如基因敲除、基因插入或碱基对替换。快速生产适合特定基因编辑实验的高品质寡核苷酸的能力对于推进基于 CRISPR 的基因组工程领域至关重要。

随着基因编辑在农业、医学和生物技术等领域的不断扩展，寡核苷酸合成市场有望大幅成长。能够根据CRISPR-Cas9 应用的独特要求提供经济高效、可靠和可定制的寡核苷酸解决方案的公司将仍然是这个充满活力和变革的领域的重要参与者，推动遗传学和生物技术的创新和进步。

细分市场洞察

应用洞察

治疗领域在寡核苷酸合成市场中占据主导地位，预计在未来几年将继续扩大。寡核苷酸合成市场的治疗领域已经确立了主导地位，并且由于几个关键因素而有望持续成长。首先，基于 RNA 的疗法，包括信使 RNA (mRNA) 疫苗和基因疗法的出现，为製药业带来了巨大的转变。寡核苷酸合成是这些变革性治疗的核心，因为它能够精确、客製化地生产对治疗效果至关重要的合成 RNA 分子。 mRNA 疫苗的成功（其在 COVID-19 大流行期间的快速发展和全球部署就是例证）强调了寡核苷酸合成在解决紧迫的医疗保健挑战方面的潜力。

其次，个人化医疗的趋势已获得相当大的发展动能。根据个别患者的基因谱客製化治疗方法需要开发高度特异性和标靶的疗法，其中许多涉及寡核苷酸。客製化寡核苷酸对于基因编辑、RNA 干扰和其他精准医学方法至关重要。随着这一趋势持续影响製药领域，寡核苷酸合成的需求必将飙升。

此外，寡核苷酸合成市场在治疗领域的应用范围不断扩大，包括遗传性疾病、癌症、传染病和罕见疾病的治疗。这些应用需要生产修饰的寡核苷酸，以增强稳定性、特异性和治疗效果，从而推动治疗领域的进一步成长。

最后，监管部门的批准和基于寡核苷酸的治疗领域不断增加的研究合作为市场注入了信心。监管机构正在为基于寡核苷酸的药物的开发和批准提供更清晰的途径，进一步推动治疗领域的扩张。

区域洞察

北美地区已成为 2022 年寡核苷酸合成市场的领导者。由于几个令人信服的原因，北美已成为 2022 年寡核苷酸合成市场的领导者。首先，该地区拥有发达且高度创新的製药和生物技术产业。尤其是美国，拥有众多领先的生物技术公司和研究机构，这些公司和研究机构推动了从基因组学研究到治疗开发等各种应用中对客製化寡核苷酸的需求。这些行业领导者的强大存在创造了一个繁荣的生态系统，促进创新、研究合作和市场成长。其次，北美受惠于医疗保健和生命科学研究的大量投资。政府资金、私人投资和风险资本纷纷涌入该地区，以支持尖端基因组研究、基因疗法和基于 RNA 的疗法。随着研究人员为其计画寻找可靠且专业的合作伙伴，这些财务支持刺激了对寡核苷酸合成服务的需求。此外，北美的监管环境有利于基于寡核苷酸的治疗。美国食品药物管理局 (FDA) 等监管机构已经制定了批准寡核苷酸药物和疗法的明确途径和指南，增强了市场信心并促进新产品的商业化。此外，该地区对精准医疗和个人化医疗保健的高度重视推动了寡核苷酸合成市场的成长。利用客製化设计的寡核苷酸来针对特定遗传标记或突变的客製化疗法符合北美的医疗保健优先事项，有助于市场扩张。最后，北美完善的基础设施和物流网络确保了高效的供应链和寡核苷酸的及时交付，进一步增强了其竞争优势。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球寡核苷酸合成市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型（合成寡核苷酸产品、试剂、设备和服务）
    • 按应用（研究、治疗和诊断）
    • 按最终用户（学术研究机构、製药和生物技术公司以及医院和诊断实验室）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图

第 6 章：北美寡核苷酸合成市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲寡核苷酸合成市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太寡核苷酸合成市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲寡核苷酸合成市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第10章：中东和非洲寡核苷酸合成市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非寡核苷酸合成
    • 沙乌地阿拉伯寡核苷酸合成
    • 阿联酋寡核苷酸合成

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购

第 13 章：全球寡核苷酸合成市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代治疗类型的威胁

第15章：竞争格局

  • 商业概览
  • 服务内容
  • 最近的发展
  • 主要人员
  • SWOT分析
    • Thermo Fisher Scientific Inc
    • Agilent Technologies, Inc.
    • Merck KGaA
    • BIO-Synthesis Inc
    • Eurofins Scientific SE
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Biogen Inc.
    • Ionis Pharmaceuticals, Inc.
    • Sarepta Therapeutics, Inc.

第 16 章：策略建议

第 17 章：关于我们与免责声明

简介目录
Product Code: 16306

The Oligonucleotide Synthesis Market, valued at USD 4.03 Billion in 2022, is expected to exhibit robust growth in the forecast period, with an anticipated Compound Annual Growth Rate (CAGR) of 13.30% through 2028.

This market occupies a prominent position in the biotechnology and pharmaceutical industries, representing the intersection of cutting-edge research and therapeutic development. In recent years, this sector has experienced remarkable expansion, driven by the growing demand for custom-designed oligonucleotides applied in various fields, including gene editing, molecular diagnostics, and drug discovery. This surge can be attributed to the rapid growth of genomics, personalized medicine, and RNA-based therapeutics, all of which heavily rely on the precise synthesis of oligonucleotides. As organizations worldwide make significant investments in genomics research and molecular diagnostics, the oligonucleotide synthesis market has become a critical enabler, granting scientists access to high-quality, tailor-made genetic material with unparalleled precision.

The competitive landscape in this market comprises a mix of well-established industry leaders and innovative startups, fostering a dynamic ecosystem. Technological advancements, such as automated synthesis platforms and novel chemical modifications, are enhancing the efficiency and adaptability of oligonucleotide production, fueling further expansion. Furthermore, regulatory approvals and industry standards play a pivotal role in ensuring the quality and safety of synthesized oligonucleotides, instilling confidence in businesses and researchers alike.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 4.03 Billion
Market Size 2028USD 8.52 Billion
CAGR 2023-202813.30%
Fastest Growing SegmentTherapeutics
Largest MarketNorth America

As the biotechnology and pharmaceutical sectors continue to grow and diversify, the oligonucleotide synthesis market is positioned for sustained expansion. Companies that can provide cost-effective, high-quality oligonucleotide solutions while remaining at the forefront of evolving technologies and regulatory requirements will undoubtedly thrive in this dynamic business environment. The strategic partnerships, research collaborations, and investments in this field are not only reshaping the landscape of life sciences but also holding the promise of groundbreaking advancements in healthcare and biotechnology. Consequently, the oligonucleotide synthesis market is a cornerstone of innovation and progress in the business world.

Key Market Drivers

RNA-Based Therapeutics

RNA-Based Therapeutics represent a transformative frontier in the pharmaceutical industry, and they have a significant impact on the oligonucleotide synthesis market. These therapeutics harness the potential of ribonucleic acid (RNA) molecules, including messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs), to modulate gene expression and treat a wide array of diseases. Oligonucleotide synthesis is at the heart of RNA-based therapeutics, as it involves the precise design and production of synthetic RNA molecules tailored to target specific genetic sequences or pathways involved in diseases.

One of the most notable breakthroughs in this field has been the development of mRNA vaccines, exemplified by the COVID-19 vaccines produced by Pfizer-BioNTech and Moderna. These vaccines employ synthetic mRNA to instruct cells to produce viral spike proteins, triggering an immune response without using weakened or inactivated viruses. The rapid success of mRNA vaccines has demonstrated the power and versatility of RNA-based therapeutics, creating a surge in demand for custom oligonucleotides used in their formulation. Oligonucleotide synthesis companies are now focusing on optimizing and scaling up production processes to meet this heightened demand.

Moreover, RNA-based therapeutics are gaining traction in treating genetic disorders, cancers, and rare diseases. ASOs and siRNAs, for instance, can selectively inhibit the expression of disease-causing genes, offering potential cures or symptom management. The design and synthesis of these oligonucleotides must be highly precise to ensure therapeutic efficacy and minimize off-target effects.

Advancements in Genomic Research

Advancements in Genomic Research have catalyzed a remarkable growth trajectory for the oligonucleotide synthesis market. Genomic research, which focuses on decoding the entirety of an organism's genetic material, has evolved rapidly, powered by technologies like Next-Generation Sequencing (NGS) and CRISPR-Cas9 gene editing. These innovations have led to a substantial increase in the demand for custom-designed oligonucleotides - short DNA or RNA sequences - that serve as the fundamental building blocks for genetic analysis, manipulation, and sequencing.

The oligonucleotide synthesis market plays a pivotal role in this genomics revolution by supplying researchers with tailor-made genetic material. Scientists require these oligonucleotides for a myriad of applications, including whole-genome sequencing, gene expression profiling, epigenetic studies, and functional genomics. As researchers aim to decipher the genetic basis of diseases, identify biomarkers, and develop targeted therapies, the need for high-quality, precise oligonucleotides continues to escalate.

Moreover, the emergence of single-cell genomics, which allows for the analysis of individual cells within heterogeneous tissues, has introduced additional complexity and demand for specialized oligonucleotides. Researchers in this field rely heavily on unique oligonucleotide probes and primers to explore the intricacies of gene expression and cellular diversity at the single-cell level.

Key Market Challenges

Efficiency and Scalability

Efficiency and scalability are critical challenges in the oligonucleotide synthesis market, driven by the escalating demand for custom oligonucleotides in various applications. Efficiency is crucial in ensuring that the synthesis processes are not only fast but also precise and error-free. Researchers and manufacturers alike require reliable and consistent results, and any inefficiencies can lead to delays, increased costs, and compromised research outcomes. Scalability, on the other hand, revolves around the industry's ability to meet the growing demand for oligonucleotides, especially with the expanding applications of genomics, gene therapy, and molecular diagnostics. Scaling up production while maintaining quality standards is a complex endeavor, often requiring significant investments in infrastructure, automation, and process optimization.

The challenge lies in striking a balance between efficiency and scalability. While automation and high-throughput technologies have improved efficiency, ensuring they are scalable to meet the surge in demand is a constant struggle. Additionally, the synthesis of long or highly modified oligonucleotides can be particularly challenging, as it may require specialized equipment and processes. Furthermore, regulatory constraints in some regions necessitate rigorous quality control and documentation, which can impact efficiency and scalability efforts.

Cost Constraints

Cost constraints in the oligonucleotide synthesis market represent a multifaceted challenge that impacts both research and commercial applications. Oligonucleotides are essential components in a wide range of genetic research, diagnostics, and therapeutic development endeavors. However, their synthesis, especially when dealing with long or chemically modified sequences, can be cost-prohibitive. Researchers operating on limited budgets often grapple with the high expenses associated with procuring custom oligonucleotides, potentially limiting the scope of their experiments. Moreover, in the context of RNA-based therapeutics, the production of large quantities of high-quality synthetic RNA molecules, such as mRNA for vaccines or gene therapies, can involve significant costs. Balancing the need for cost-effective oligonucleotides with the requirement for precision and purity is a constant challenge for the industry.

Companies in the oligonucleotide synthesis market also face cost-related pressures. While advancements in automation and synthesis technologies have improved efficiency and reduced costs to some extent, competition within the market necessitates competitive pricing. This can be challenging for companies looking to maintain profit margins while investing in research and development to stay at the forefront of the field. Additionally, the incorporation of chemical modifications or specialized sequences can significantly increase production costs, further complicating the cost-effectiveness equation.

Key Market Trends

Therapeutic Advancements

Therapeutic advancements represent a pivotal trend in the oligonucleotide synthesis market, ushering in a new era of precision medicine and targeted therapies. This trend is characterized by the development and commercialization of RNA-based therapeutics, including messenger RNA (mRNA) vaccines and gene therapies, which rely heavily on custom oligonucleotide synthesis. mRNA vaccines, exemplified by the COVID-19 vaccines from Pfizer-BioNTech and Moderna, have demonstrated the transformative potential of synthetic RNA molecules in eliciting immune responses without using weakened or inactivated viruses. Oligonucleotide synthesis is at the core of these vaccines, producing precisely designed mRNA sequences encoding viral antigens. Beyond vaccines, oligonucleotides play a crucial role in gene therapies, where they are used to modify, repair, or replace defective genes responsible for genetic disorders.

The oligonucleotide synthesis market is integral to therapeutic advancements as it provides the essential raw materials - custom-designed oligonucleotides - with high precision and purity. This allows researchers and pharmaceutical companies to develop RNA-based therapeutics with unprecedented accuracy and efficacy. As research in RNA-based treatments expands to address various diseases, including cancer, rare genetic disorders, and autoimmune conditions, the oligonucleotide synthesis market is poised to grow exponentially. It will continue to serve as a cornerstone of innovation and progress in healthcare, offering the means to manufacture these transformative therapeutics on a scale required to meet global healthcare needs. Consequently, staying at the forefront of oligonucleotide synthesis technologies is critical for companies aiming to contribute to this dynamic and rapidly evolving field.

Gene Editing and CRISPR-Cas9

Gene editing, particularly through the revolutionary CRISPR-Cas9 technology, has emerged as a major driving force in the oligonucleotide synthesis market. CRISPR-Cas9, a versatile genome-editing tool, relies on the precise design and synthesis of oligonucleotides to target and modify specific DNA sequences within an organism's genome. Oligonucleotides, known as guide RNAs (gRNAs), are synthetically engineered to complement the target DNA, guiding the Cas9 enzyme to the desired genomic location for editing. This technology has unlocked new possibilities in genetic research, enabling researchers to manipulate genes with unprecedented precision for applications ranging from fundamental research to therapeutic interventions.

The oligonucleotide synthesis market plays a pivotal role in supporting CRISPR-Cas9 applications by providing custom-designed gRNAs and donor DNA templates for gene editing. Researchers and biotechnology companies require these oligonucleotides to facilitate precise modifications, such as gene knockouts, gene insertions, or base pair substitutions. The ability to rapidly produce high-quality oligonucleotides tailored to specific gene-editing experiments is crucial for advancing the field of CRISPR-based genome engineering.

As gene editing continues to expand in areas like agriculture, medicine, and biotechnology, the oligonucleotide synthesis market is poised for substantial growth. Companies that can offer cost-effective, reliable, and customizable oligonucleotide solutions tailored to the unique requirements of CRISPR-Cas9 applications will remain essential players in this dynamic and transformative field, driving innovation and progress in genetics and biotechnology.

Segmental Insights

Application Insights

The Therapeutic Segment dominates the Oligonucleotide Synthesis market and is predicted to continue expanding over the coming years. The therapeutic segment of the oligonucleotide synthesis market has established dominance and is poised for sustained growth due to several key factors. Firstly, the advent of RNA-based therapeutics, including messenger RNA (mRNA) vaccines and gene therapies, has created a seismic shift in the pharmaceutical industry. Oligonucleotide synthesis is at the core of these transformative treatments, as it enables the precise and customized production of synthetic RNA molecules critical for therapeutic efficacy. The success of mRNA vaccines, exemplified by their rapid development and global deployment during the COVID-19 pandemic, has underscored the potential of oligonucleotide synthesis in addressing pressing healthcare challenges.

Secondly, the trend toward personalized medicine has gained considerable momentum. Tailoring treatments to individual patients' genetic profiles requires the development of highly specific and targeted therapies, many of which involve oligonucleotides. Customized oligos are essential for gene editing, RNA interference, and other precision medicine approaches. As this trend continues to shape the pharmaceutical landscape, the demand for oligonucleotide synthesis is set to soar.

Furthermore, the oligonucleotide synthesis market is witnessing an expanding range of applications within therapeutics, including the treatment of genetic disorders, cancer, infectious diseases, and rare conditions. These applications necessitate the production of modified oligonucleotides that enhance stability, specificity, and therapeutic effectiveness, driving further growth in the therapeutic segment.

Lastly, regulatory approvals and increasing research collaborations in the oligonucleotide-based therapeutic space have instilled confidence in the market. Regulatory agencies are providing clearer pathways for the development and approval of oligonucleotide-based drugs, further propelling the therapeutic segment's expansion.

Regional Insights

The North America region has established itself as the leader in the Oligonucleotide Synthesis Market in 2022. North America has emerged as the frontrunner in the oligonucleotide synthesis market in 2022 for several compelling reasons. Firstly, the region boasts a well-developed and highly innovative pharmaceutical and biotechnology industry. The United States, in particular, is home to numerous leading biotech companies and research institutions that drive the demand for custom oligonucleotides in various applications, from genomics research to therapeutic development. The robust presence of these industry leaders has created a thriving ecosystem that fosters innovation, research collaborations, and market growth. Secondly, North America benefits from a substantial investment in healthcare and life sciences research. Government funding, private investments, and venture capital have poured into the region to support cutting-edge genomic studies, gene therapies, and RNA-based therapeutics. These financial backing fuels the demand for oligonucleotide synthesis services, as researchers seek reliable and specialized partners for their projects. Additionally, the regulatory environment in North America is conducive to oligonucleotide-based therapeutics. Regulatory agencies like the U.S. Food and Drug Administration (FDA) have developed clear pathways and guidelines for the approval of oligonucleotide drugs and therapies, instilling confidence in the market and facilitating the commercialization of novel products. Moreover, the region's strong emphasis on precision medicine and personalized healthcare has propelled the growth of the oligonucleotide synthesis market. Tailored therapies that utilize custom-designed oligonucleotides to target specific genetic markers or mutations align with North America's healthcare priorities, contributing to market expansion. Lastly, North America's well-established infrastructure and logistics networks ensure efficient supply chains and timely delivery of oligonucleotides, further enhancing its competitive advantage.

Key Market Players

  • Thermo Fisher Scientific Inc
  • Agilent Technologies, Inc.
  • Merck KGaA
  • BIO-Synthesis Inc
  • Eurofins Scientific SE
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Biogen Inc.
  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.

Report Scope:

In this report, the Oligonucleotide Synthesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oligonucleotide Synthesis Market, Product Type:

  • Synthesized Oligonucleotide Products
  • Reagents
  • Equipment
  • Services

Oligonucleotide Synthesis Market, Application:

  • Research
  • Therapeutics
  • Diagnostics

Oligonucleotide Synthesis Market, End User:

  • Academic Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Hospital & Diagnostic Laboratories

Oligonucleotide Synthesis Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • Italy
  • France
  • Spain
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Oligonucleotide Synthesis Market.

Available Customizations:

  • Oligonucleotide Synthesis Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oligonucleotide Synthesis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Synthesized Oligonucleotide Products, Reagents, Equipment, and Services)
    • 5.2.2. By Application (Research, Therapeutics, and Diagnostics)
    • 5.2.3. By End User (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, and Hospital and Diagnostic Laboratories)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map

6. North America Oligonucleotide Synthesis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Oligonucleotide Synthesis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Oligonucleotide Synthesis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Oligonucleotide Synthesis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Oligonucleotide Synthesis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Oligonucleotide Synthesis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Oligonucleotide Synthesis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. Italy Oligonucleotide Synthesis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. France Oligonucleotide Synthesis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Oligonucleotide Synthesis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Oligonucleotide Synthesis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Oligonucleotide Synthesis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Oligonucleotide Synthesis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Oligonucleotide Synthesis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Oligonucleotide Synthesis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Oligonucleotide Synthesis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Oligonucleotide Synthesis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Oligonucleotide Synthesis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Oligonucleotide Synthesis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Oligonucleotide Synthesis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Oligonucleotide Synthesis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Oligonucleotide Synthesis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Oligonucleotide Synthesis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Oligonucleotide Synthesis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions

13. Global Oligonucleotide Synthesis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Thermo Fisher Scientific Inc
    • 15.5.2. Agilent Technologies, Inc.
    • 15.5.3. Merck KGaA
    • 15.5.4. BIO-Synthesis Inc
    • 15.5.5. Eurofins Scientific SE
    • 15.5.6. Danaher Corporation
    • 15.5.7. Agilent Technologies, Inc.
    • 15.5.8. Biogen Inc.
    • 15.5.9. Ionis Pharmaceuticals, Inc.
    • 15.5.10. Sarepta Therapeutics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer